NYSE: CVS · Retail Trade
Which UK funds hold CVS Health Corporation (CVS)?
CVS Health Corporation (CVS) is not among the ten largest holdings of any UK fund Fundology covers. It appears further down the published holdings of 154 funds. 46 swap-based funds also list CVS Health Corporation (CVS) in the substitute baskets they hold as collateral; they track different indices through swaps and are not counted as holders.
UK funds that hold CVS Health Corporation
No covered fund lists this company today
Many funds publish only their ten largest positions, so a fund can own a company without it appearing here.
Funds that hold it further down
154 more funds list CVS Health Corporation below their ten largest holdings.
Create a free account to see every fund that holds this company, at any weight
Sign-up takes an email address. There is no card to enter and nothing to pay.
About CVS Health Corporation
CVS Health Corporation is listed on NYSE under the symbol CVS, in the retail trade sector. Its market value was about $114.3bn (in US dollars) on 13/11/2026.
A fund’s weight in a company is the share of the fund’s money held in that company’s shares. A weight of 5% in a fund worth £1 billion is about £50 million. Index funds hold companies in proportion to their size in the index, so the largest companies appear in many funds at similar weights.
The list above is drawn from the funds’ published holdings, each dated, and names the funds where CVS Health Corporation is one of the ten largest holdings — the part of every fund page open to anyone. Some funds publish only their largest ten, so a fund can hold CVS Health Corporation without it appearing in any list here. When two funds both hold the same large companies, owning both can be closer to owning one than it looks: the comparison page measures that overlap when both funds publish enough of their holdings.
Share price
- Latest price
- $89.35
- −0.49%on the day
- 52-week range
- $69.51–$110.68
- Price change, 1 year
- +12.8%
- Price change, this year
- +12.7%
- Market value
- $114.3bn
- Price to earnings (12 months)
- 10.4
- Dividend yield (12 months)
- 2.96%
As of , at least 15 min delayed